How Often to Check aPTT When on Heparin
Check aPTT 4-6 hours after starting heparin infusion or after any dose change, then continue every 4-6 hours until therapeutic range is achieved; once stable in therapeutic range, check aPTT daily. 1, 2, 3
Initial Monitoring Protocol
- Draw the first aPTT 4-6 hours after initiating the heparin infusion to assess initial anticoagulation response and guide dose adjustments 1, 2, 3
- Continue checking aPTT every 4-6 hours after each dose adjustment until the therapeutic range is consistently achieved 1, 2, 3
- The 4-6 hour interval allows sufficient time for heparin to reach steady-state pharmacokinetics and provides an accurate reflection of the anticoagulant effect 3
Therapeutic Target Range
- Target an aPTT of 60-85 seconds, which corresponds to a heparin level of 0.35-0.7 U/mL by anti-factor Xa assay 2, 4, 3
- Alternatively, target an aPTT ratio of 1.5-2.5 times the control value, though this must be calibrated to your institution's specific reagent and coagulometer 1
- The traditional 1.5-2.5 ratio is vulnerable to significant inter-laboratory variation, with the same heparin concentration producing aPTT ratios ranging from 1.6-2.7 to 3.7-6.2 depending on reagent sensitivity 1
Maintenance Monitoring
- Once therapeutic aPTT is achieved and remains stable for two consecutive measurements, reduce monitoring frequency to every 24 hours 1, 2
- Monitor platelet count at baseline, on day 5, then every 2-3 days throughout heparin therapy to detect heparin-induced thrombocytopenia 2, 3
- Check hemoglobin/hematocrit at least daily during UFH therapy 1
Special Considerations for Renal Impairment
- Patients with renal impairment require the same aPTT monitoring frequency (every 4-6 hours initially, then daily when stable) because unfractionated heparin is primarily cleared hepatically, not renally 1
- At high doses, heparin does have some renal clearance, making aPTT monitoring even more critical in renal dysfunction to avoid accumulation 1
- Weight-based dosing nomograms should still be used, with dose adjustments based on aPTT results rather than preemptive dose reductions 1, 3
Critical Pitfalls to Avoid
- Subtherapeutic anticoagulation (aPTT <50 seconds or <1.5 times control) increases thrombotic risk 15-fold compared to therapeutic anticoagulation 2, 4
- aPTT values of 50-59 seconds still carry increased thrombotic risk despite appearing "close" to therapeutic 2, 4
- aPTT >90 seconds increases bleeding risk without additional antithrombotic benefit and requires immediate dose reduction 2, 4
- Never hold therapeutic anticoagulation solely to obtain a laboratory value when the underlying thrombotic condition remains active 5
- Delays in laboratory turnaround time can result in prolonged periods of over- or under-anticoagulation and should be minimized 1
When aPTT Monitoring Is Problematic
- Consider switching to anti-factor Xa monitoring (target 0.35-0.7 U/mL) if aPTT results are unreliable or unobtainable 1, 2, 5
- This is particularly important in critically ill patients with hyperinflammatory states (such as COVID-19), where elevated factor VIII and fibrinogen cause heparin resistance and make aPTT unreliable 1
- In heparin resistance, the aPTT may normalize despite adequate heparin levels by anti-Xa assay, potentially leading to dangerous overdosing if aPTT alone guides therapy 1
- Anti-factor Xa monitoring is less dependent on pre-analytical conditions and less vulnerable to laboratory interference than aPTT 1
Dose Adjustment Algorithm
When aPTT results return, adjust according to weight-based nomograms 4, 3:
- aPTT <35 seconds: Give 80 units/kg bolus, increase infusion by 4 units/kg/hour 4
- aPTT 35-45 seconds: Give 40 units/kg bolus, increase infusion by 2 units/kg/hour 4
- aPTT 46-70 seconds: No change needed 4
- aPTT 71-90 seconds: Decrease infusion by 2 units/kg/hour 4
- aPTT >90 seconds: Hold infusion for 1 hour, then decrease by 3 units/kg/hour 4